ripekg:evaluation/RIPEA62FEC5B159F50CEC |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-human-1-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-human-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-human-2-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-human-overall |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-2-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:publication-details/RIPEA62FEC5B159F50CECOnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:registry-evidence/RIPEA62FEC5B159F50CEC |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
rdf:type |
rdfs:Resource |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
rdf:type |
owl:Thing |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
rdf:type |
ripe:ResearchIntegrityAssessmentResearch integrity assessment |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
rdf:type |
tido:Case |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripe:assesses |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:integrity-assessment-question/post-publication-notices/1.0.01.2. Does the study have an associated expression of concern or other relevant post-publication notice? |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:integrity-assessment-question/post-publication-notices/1.0.0post-publication notices |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.01.3. Do other studies by the research team highlight causes for concern? |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.0research-team-related concerns |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:integrity-assessment-question/retraction-status/1.0.01.1. Does the study have an associated retraction? |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:integrity-assessment-question/retraction-status/1.0.0retraction status |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:integrity-assessment-question/study-registration/1.0.02.2. Are there concerns relating to the timing or absence of study registration? |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:integrity-assessment-question/study-registration/1.0.0study registration |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:overall-integrity-assessment-question/1.0.0What is the overall integrity assessment of the study? |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
tido:investigates |
ripekg:overall-integrity-assessment-question/1.0.0overall integrity assessment |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |